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Introduction
Non-medical prescribing (NMP) is utilised in a diversity of ways
by a variety of health professions internationally.1 In the UK the
two types of NMP that are used by prescribers are supplementary
non-medical prescribing (sNMP) and independent non-medical
prescribing (iNMP).2,3 Clinicians prescribing via sNMP use a clinical
management plan in partnership with a medical or dental
practitioner, whereas iNMP requires the clinician to be entirely
autonomous, prescribing medicines based on their individual
clinical reasoning and judgments.2 Independent physiotherapy
prescribing was introduced in the UK in 2012, with the ﬁrst
physiotherapists qualifying as independent prescribers in 2013.4
Physiotherapists in Australia have now expressed an interest in
NMP and commenced national processes to evaluate potential
clinical need, quality and safety issues.5 The implementation and
legal utilisation of NMP will require healthcare policy modiﬁcation
and legislative reform. Organisational objectives, professional
issues and societal inﬂuence must be reﬂected in national and
local policy if change is to occur.6 However, robust research is
required to guide the implementation of evidence-based NMP
practice and the necessary changes in policy.
Pharmacist prescribing has demonstrated clinical effectiveness
for the management of chronic pain in primary care and
postoperative pain in a tertiary surgical unit, with statistically
signiﬁcant improvements in pain intensity (p = 0.02), anxiety and
depression (p = 0.022),7 and reduced prescribing errors
(p < 0.001)8 compared to traditional practices.7–9 The effectiveness
of prescribing in physiotherapy-speciﬁc settings has not yet been
examined because the instigation of independent physiotherapy
prescribing is recent. Physiotherapists must ensure that they learn
from the evidence from other professions and their application of
strategies to implement and utilise NMP.10 The analysis and
synthesis of this evidence is paramount to understand the factors
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Question: What are the factors that affect the implementation or utilisation of independent non-medical
prescribing (iNMP)? Design: Mixed-methods systematic review. Two reviewers independently
completed searches, eligibility and quality assessments. Data sources: Pre-deﬁned search terms were
utilised to search electronic databases. Reference lists, key journals and grey literature were searched
alongside consultation with authors/experts. Eligibility criteria for included studies: Qualitative and
quantitative studies investigating independent prescribing by any non-medical professional group. Study
participants included any stakeholders involved in actual or proposed iNMP. Measurements reported on
data describing stakeholders’ perceptions and experiences of the barriers to/facilitators of iNMP. Results:
A total of 43 qualitative and seven quantitative studies from three countries (n = 12, 117 participants)
were included. Quality scores varied from 9 to 35 (Quality Assessment Tool for Studies with Diverse
Designs, 0 to 48). Qualitative data were synthesised into four themes (and subthemes): systems
(government and political, organisational, formulary); education and support (non-medical prescribing
(NMP) courses/continuous professional development (CPD)); personal and professional (medical
profession, NMP professions, service users); and ﬁnancial factors. Quantitative data corroborated the
qualitative themes. Integration of the qualitative themes and quantitative data enabled the development
of a NMP implementation framework. Conclusion: Barriers to and facilitators of the implementation and
utilisation of iNMP are evident, demonstrating multifactorial and context-speciﬁc variables within four
explicit themes. Professional bodies, politicians, policy and healthcare managers and clinicians could use
the resulting NMP implementation framework to ensure the safe and successful implementation and
utilisation of NMP. Clinical physiotherapists and other clinicians should consider whether these variables
have been adequately addressed prior to adopting NMP into their clinical practice. Registration:
PROSPERO CRD42015017212. [Noblet T, Marriott J, Graham-Clarke E, Rushton A (2017) Barriers to and
facilitators of independent non-medical prescribing in clinical practice: a mixed-methods
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acting to enable or block iNMP10,11 because successful implemen-
tation of innovations (such as iNMP) depend on exploiting
facilitators and planning for potential barriers.6,12
Therefore, the speciﬁc research question for this systematic
review was:
What are the factors that affect the implementation or
utilisation of independent non-medical prescribing (iNMP)?
Method
A mixed-methods systematic review was conducted according to
a pre-deﬁned protocol that followed the Cochrane Handbook and
was reported in accordance with the PRISMA statement.13–15 The
protocol was registered with PROSPERO (CRD42015017212).16,17 A
sequential exploratory approach harmonised the qualitative and
quantitative literature.18
Identiﬁcation and selection of studies
A comprehensive pre-determined search strategy of the
databases outlined in Box 1 was developed in MEDLINE as shown
in Appendix 1 (see eAddenda for Appendix 1), and customised for
the other databases.19 The other information sources outlined in
Box 1 were also searched. Where eligible pilot studies were
identiﬁed, the reviewers searched for the full studies. Authors were
contacted if full studies were not retrieved, to conﬁrm the
existence of a full study and/or any other related (un)published
literature. Reference lists of included studies were searched,20,21
and subject experts were consulted to detect any further
studies.13,20–22
Eligibility criteria were deﬁned a priori. The inclusion criteria
are presented in (Box 2). Studies not written in English were
excluded once identiﬁed, in order to provide information on
potential bias.19 Descriptive papers, editorials and opinion papers
were excluded due to their potential internal bias.23 All studies
satisfying the eligibility criteria were included.
Two investigators completed the literature searches (TN/EGC);
each independently evaluated titles and abstracts for inclusion. A
third reviewer (AR) mediated in cases of disagreement. Where
exclusion was not possible based on title and abstract, the
investigators independently reviewed the full text. All studies
fulﬁlling eligibility criteria were included.
Data extraction
Qualitative data
One reviewer (TN) used commercial softwarea to extract data
assessing stakeholders’ experiences of the barriers to and
facilitators of iNMP.20 A second reviewer (EGC) independently
reviewed data extraction by ensuring that all relevant data were
extracted. Differences in opinion were resolved at a consensus
meeting.22
Quantitative data
Data pertaining to barriers and facilitators were extracted from
the quantitative studies independently by the two reviewers (TN,
EGC) using data extraction sheets speciﬁc to the study objectives.20
The third reviewer (AR) checked for consistency, clarity and aided
resolution throughout the process.
Assessment of study quality
The comprehensiveness of reporting and transparency was
evaluated using the Quality Assessment Tool for Studies with
Diverse Designs (QATSDD),23 producing a quality rating score for
each study. Good validity, inter-rater reliability and test-retest
reliability have been established for the QATSSD across a diversity
of study designs, demonstrating its value for consistent quality
assessment in mixed-methods designs.23,24 Two researchers (TN
and EGC) independently assessed each study, with disagreements
discussed and resolved.22
Box 1. Information sources.
Databases
 CINAHL, EMBASE, MEDLINE, AMED, NICE, Medicines
Complete, HMIC, ASSIA, Web of Science, Health and
Safety Science Abstracts
Internet sites
 PUBMED, Turning Research into Practice, Google Scholar,
Royal College of Nursing, Royal Pharmaceutical Society,
King’s Fund, National Institute of Clinical Excellence,
Department of Health, National Prescribing Centre,
Chartered Society of Physiotherapy, Society of
Chiropodists and Podiatrists, American Association of
Nurse Practitioners, Australian College of Nurse
Practitioners, Canadian Pharmacists Association,
Optometry Australia, British Optometry Association
National Research Register
Hand searching of key journals
System for Information on Grey Literature, unpublished re-
search
Expert opinion
Reference lists of all included papers
Box 2. Inclusion criteria.
Population
 Independent non-medical prescribers from any professional group with legal authorisation to prescribe medicines independently,82
or stakeholders engaged with non-medical prescribers/NMP services.
Intervention
 NMP provided by a professional group with legal authorisation to prescribe medicines independently.82
Comparator(s)/control
 Not applicable
Qualitative study designs
 Any empirical qualitative study that describes the sampling
strategy, data collection procedures, and type of data analysis.83
Quantitative study designs
 Any design reporting quantitative data.13
Qualitative outcomes
 Consumers’, carers’ and/or healthcare professionals’ perceptions
and experiences of the barriers to and/or facilitators of iNMP.13
Quantitative outcomes
 Quantitative survey questions assessing: the barriers to
and/or facilitators of iNMP; economic comparisons; patient,
staff and/or educational satisfaction/expectation; location
comparisons; and health sector/specialty comparisons.13
iNMP = independent non-medical prescribing, NMP = non-medical prescribing.
Noblet et al: Barriers to and facilitators of non-medical prescribing222
Data analysis and synthesis of results
A three-step process of analysis synthesised the qualitative and
quantitative data.
Qualitative component
Qualitative data were synthesised using a thematic analytical
approach.25 One reviewer (TN) undertook line-by-line coding of
data relating to barriers and facilitators of iNMP. Data were
grouped into descriptive themes and then developed into
analytical themes/sub-themes.25 Two reviewers reviewed prelim-
inary themes/sub-themes; they re-read all included studies to
ensure that the identiﬁcation of all relevant data was complete.25
The themes/sub-themes were then scrutinised by a panel of
experts to agree upon the ﬁndings. Characteristics and outcomes of
the included studies were tabulated.
Quantitative component
Data from quantitative survey questions assessing barriers and
facilitators were extracted from the quantitative studies. Studies’
characteristics and outcome data were tabulated. A narrative
analysis of the quantitative evidence was undertaken independent
of the qualitative literature analysis.21
Integration
The qualitative and quantitative data were compared through
an integration process to determine agreement or disagreement
within identiﬁed themes/sub-themes.18,26 Data were tabulated
into an integration matrix.25–27 Whether qualitative and quantita-
tive data corroborated and conﬁrmed ﬁndings was observed and
reported. To demonstrate the key factors that affect the
implementation and utilisation of iNMP, the integrated data were
used to develop an implementation framework.25
Results
Flow of studies through the review
As shown in Figure 1, 3247 (3244 from database searches, three
from reference lists) potentially relevant studies were identiﬁed.
No unpublished studies were identiﬁed. Following removal of
duplicates (n = 247), 3000 citations remained. Screening by title
and abstract excluded 2876 studies, with full texts of the remaining
124 studies examined in detail. This resulted in 43 qualitative
studies and seven quantitative studies, totalling 50 included
studies.
Characteristics of qualitative studies
Study characteristics
Characteristics of the qualitative studies are summarised in the
ﬁrst three columns of Table 1. More detailed characteristics are
available in Table 2 (see the eAddenda for Table 2). Studies were
undertaken in three countries: 39 (91%) in the UK, two (5%) in
Canada and two (5%) in the USA.
Study methods
Of the 43 included studies, 24 (56%) used interviews, 11 (26%)
used surveys, and one (2%) used focus groups as the primary
research method. The remaining seven (16%) studies used a mixed-
methods approach including surveys/interviews/focus groups/
non-participant observation.
Participants
Across the 43 studies, 7344 participants were recruited. In two
instances, data from one sample were reported across two studies.
Where sample populations were duplicated across multiple
studies reporting different data, participants were counted
once.28–31 Table 3 summarises the stakeholder groups engaged
Total records retrieved
(n = 3247 )
Full-text articles 
ass essed  for eli gibili ty 
(n = 124 )
Stud ies included  in 
qualitative sy nthe sis 
(n = 43 )
Stud ies included  in 
integ ration  (n = 50)
Full-text articles exc luded  (n = 74 )
• doe s no t an swer stud y que stion  
(n = 56 )
•
•
not empirical eviden ce (n = 11 )
con ference ab stract (n = 7)
Records sc reened  by 
title and  ab stract
(n = 3000 )
Records exc lude d
(n = 2876 )
Records iden tified  through  
databa se sea rching
(n = 3244 )
Add itiona l records iden tified  
through  othe r sou rces
(n = 3)
Dupli cates removed
(n = 247 )
Stud ies included  in 
quantitative sy nthe sis 
(n = 7)
Figure 1. Flow of studies through the review (adapted from Moher et al).19
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with each data collection method. A few participants (0.4%) had no
deﬁned role, being described as general stakeholders.
Intervention
Most of the included studies investigated nurse iNMP (n = 33,
77%), with pharmacists being the only other professional group
that was speciﬁcally investigated (n = 6, 14%). Two studies
investigated both nurse and pharmacist iNMP together (5%), with
a further two studies investigating iNMP from all potential
professional groups (5%).
Setting
Study settings included both community healthcare (40%) and
hospital settings (14%), with most studies conducted across both
healthcare settings (47%). A total of 42% of included studies
encompassed all healthcare specialties (n = 18). The remaining
studies examined: mental health (16%), paediatrics (7%), derma-
tology (5%), general practice (5%), oncology and palliative care (5%),
diabetes (5%), pain management (5%), human immunodeﬁciency
virus (2%), district nursing (2%), addiction (2%), dementia (2%) and
cardiology (2%).
Table 1
Characteristics and quality of the included qualitative studies (n = 43).
Study Setting Specialty Total
(n)
Mode of data collection: number of participants from each profession Qualitya
(0 to 48)
Avery32 Community/Hospital Various 110 Survey: 80 nurses, 3 midwives, 2 pharmacists. Interview: 16 nurses,
5 doctors, 1 pharmacist, 3 managers
18
Bennett45 Community HIV 8 Survey: 8 nurses. Interview: 8 nurses 19
Bradley51 Community/Hospital Various 45 Face-to-face interview: 31 nurses. Telephone interview: 14 nurses 19
Bradley36 Community/Hospital Mental Health 15 15 nurses 9
Carey37 Hospital Paediatrics 21 7 nurses, 11 doctors, 3 managers 20
Carey38 Community Dermatology 40 11 prescribing nurses, 12 doctors, 11 admin staff, 6 non-prescribing nurses 19
Courtenay39 Hospital Paediatrics 14 7 nurse prescribers, 4 consultant doctors, 3 managers 30
Courtenay33 Community/Hospital Various 28 28 NMP leads 25
Cousins62 Community General Practice 6 6 nurses 24
Downer55 Community District nursing 8 8 district nurses 20
Earle57 Community Mental Health 8 2 prescribing nurses, 6 service users 26
Glod48 Community/Hospital Mental Health 1352 1352 advance practice nurses 27
Guirguis74 Community Various 38 13 prescribing pharmacists, 25 non-prescribing pharmacists 32
Hales56 Community/Hospital Mental Health 32 32 advanced practice nurses 9
Hall75 Community Various 21 21 community nurses 9
Hall40 Community Various 67 Interview: 11 district nurses, 10 health visitors, 2 practice nurses. Survey:
44 NMP leads
27
Hill76 Community Addiction Services 97 86 service users, 5 prescribing pharmacists, 6 doctors 14
Hobson49 Community/Hospital Various 18 18 service users 31
Jones50 Hospital Various 196 Interview: 3 prescribers (profession n/s), 7 mentors/colleagues, 8 managers.
Structured non-participant observation: 2 nurse prescribers, 2 doctors,
52 consultations. Survey: 122 service users
35
Kelly54 Community General Practice 151 151 community practice nurses 17
Lewis-Evans58 Community Various 7 7 nurses 28
Luker77 Community Various 256 256 service users (157 pre-prescribing, 148 post prescribing) 5
Maclure41 Community/Hospital Various 1855 1855 service users 18
Makowsky59 Community Various 38 38 pharmacists 32
McCann42 Community/Hospital Various 105 105 pharmacists 20
McCann43 Community/Hospital Various 35 11 pharmacists, 11 doctors, 13 other stakeholders 25
Mulholland65 Hospital Paediatrics 45 45 pharmacists 11
Nolan53 Community/Hospital Mental Health 51 51 nurses 17
Page64 Hospital Dementia 20 13 service users, 7 non-prescribing staff 19
Ross34 Community/Hospital Mental Health 45 33 nurses. Focus group: 12 nurses 34
Ryan-Woolley29 Community/Hospital Oncology/Palliation 2252 2252 nurses 15
Ryan-Woolley28 Community/Hospital Oncology/Palliation 2252 2252 nurses 19
Scrafton35 Hospital Various 6 6 nurses 29
Shannon78 Community/Hospital Cardiology 21 Focus group: 21 doctors. Interview: 21 doctors 24
Stenner61 Community/Hospital Dermatology 18 12 doctors, 6 non-prescribing nurses 22
Stenner46 Community/Hospital Diabetes 31 10 prescribing nurses, 9 doctors, 9 admin staff, 3 non-prescribing nurses 21
Stenner30 Community/Hospital Pain Management 26 26 prescribing nurses 22
Stenner31 Community/Hospital Pain Management 26 26 prescribing nurses 28
Stenner60 Community Diabetes 41 41 service users 23
Travers44 Community Various 7 Focus group: 7 nurses. Interview: 7 nurses 10
While52 Community Various 91 91 community nurses 20
Wix79 Community/Hospital Mental Health 78 78 service users 10
Young80 Community Various 5 5 community nurses 19
Admin = administrative, HIV = human immunodeﬁciency virus, NMP = non-medical prescribing, n/s = not stated.
a Quality Assessment Tool for Studies with Diverse Designs.23
Table 3
The number of stakeholders engaged with each data collection method.
Stakeholder Surveys (n) Interviews (n) Focus groups (n) Observation (n) Total
n (%)
Nurses 4053 222 42 2 4319 (59)
Service users 2055 420 0 52 2527 (34)
Pharmacists 152 93 0 0 245 (3)
Medical doctors 0 91 21 2 114 (2)
NMP leads 44 28 0 0 72 (1)
General 0 30 0 0 30 (<1)
Admin staff 0 20 0 0 20 (<1)
Managers 0 17 0 0 17 (<1)
Total 6304 921 63 56 7344 (100)
Admin = administrative, NMP = non-medical prescribing.
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Quality assessment
Quality scores of the qualitative studies are summarised in
Table 1 and ranged from 9 to 35. Detailed quality criteria
information is provided in Table 4 (see eAddenda for Table 4).
Results and synthesis of qualitative studies
Identiﬁed factors were categorised into four major themes:
systems factors; education and support factors; personal and
professional factors; and ﬁnancial factors. The major themes and
their subthemes are described below. Each theme can be both a
barrier and facilitator, depending on context. Table 5 lists the
studies that reported or discussed each theme, providing illustra-
tive quotations from participants or study authors for each sub-
theme. It is acknowledged that the themes interact with each
other.
Systems factors
Participants in 32 (74%) of the included studies highlighted a
range of system factors that may act as either barriers or facilitators
to implementing NMP, including government and political factors,
organisational factors and practices, and delivery in terms of
formulary.
Government and political factors: Participants perceived that
factors such as political motive, government funding availability
for education, adequate and appropriate political drive, and
strategic/cohesive planning at all government levels could facili-
tate or impede NMP use.32–35 Speciﬁcally, participants recognised
facilitators such as the importance of access to funding and the
need for implementation pressure on health services from
government.32,35 Potential barriers were identiﬁed as the absence
of political leadership, and politically driven promotion of NMP as a
cheap alternative to medical prescribing, rather than promotion of
non-medical prescribers with the knowledge and skills to enhance
patient access to care.33,34
Organisational factors: Participants highlighted the importance
of robust local clinical governance policies, pathways and pro-
cedures in place prior to training non-medical prescribers,28,31–44
with standardised local policy to ensure quality of care and patient
safety, and lines of authority and responsibility clearly deﬁned.32,34
Scope, parameters, boundaries and guidelines should be clearly
documented and readily accessible to all stakeholders.34 Adequate
support mechanisms with time and funding for continuing
professional development (CPD) activities should also be docu-
mented.30,38 Further, participants deemed it essential that
institutions ensure access to patients’ medical records where
required, with clear guidelines regarding clinical documentation,
incident reporting and communication.40,41,43 Clinicians must
prescribe within their individual competency, with transparent
policies to alleviate concerns from pressure to prescribe outside of
scope from senior colleagues and managers.35,42–44 Participants
recommended that databases should be developed locally to:
enable prescribing practice audit; ensure evidence-based clinical
practice, transparency and accountability;33 and showcase poten-
tial economic savings.36
Participants noted that ﬁnancial processes enabling infrastruc-
ture, administration and logistics must be in place prior to
implementation.33,45 Excessive delays in access to prescription
pads or electronic prescribing were a fundamental issue that
prevented clinicians from utilising their prescribing skills.33,34,40,46
Both local and national administrative processes required for
prescriber authorisation and to start prescribing were seen as
barriers.40,42,47,48 Processes were described as long and arduous,
resulting in many potential prescribers feeling that the outcome
was not worth the stress and effort,47,48 or loss of conﬁdence by
qualiﬁed prescribers by the time they were given the authority and
facilities to prescribe.47 The availability of appropriate clinical
facilities was considered important.49 Absence of a consultation
room in some facilities may compromise assessment of patients’
needs.49
Facilitation of NMP was recognised when a strategic, collabo-
rative and consultative approach to develop and implement it into
a service was adopted.32,33,50 This reduced the risk of professional
territorialism, and ensured that the focus remained on patient-
centred care rather than a speciﬁc profession’s interests.51 A lack of
vision regarding the beneﬁts of commissioning innovative areas of
practice was reported as a barrier.33 It was recognised that for NMP
to become embedded in practice, service development and
implementation should reﬂect the needs of the local community
and address issues such as workforce planning, CPD requirements
and clinical frameworks development.34,36,37,51 Long-term viability
of NMP services was highlighted as a historical area of weakness.
One study36 recommended that if NMP were to develop in a health
service, four or ﬁve non-medical prescribers should be trained to
ensure support and succession planning. Participants recognised
that well-deﬁned selection criteria aimed at selecting the best
candidates for NMP training was beneﬁcial.37,39 Conversely, others
warned that overly restrictive criteria might be a barrier to NMP
expansion into new areas of practice.33 Another key barrier was a
fragmented health service caused by the division of funding for
service provision and prescription drugs, plus geographical
restrictions due to law, regulation or organisational jurisdic-
tion.33,36,40 To counteract this, innovative service design alongside
utilising an individual profession’s skills, talents and mastery were
recommended. Simply replacing medical staff in conventional
clinical environments with non-medical prescribers, where
budgets, or medical staff availability dictate practice, was
perceived as short sighted.33,38
Formulary: Most participants identiﬁed a ‘limited formulary’ as
a potential barrier. Due to the dynamic nature of drug availability,
and constantly evolving evidence-based practice, frustrations were
frequently felt because of practice limitations secondary to
formulary restrictions.31,44,52,53 Participants reported situations
when they could not prescribe appropriate medication because it
was outside an out-dated formulary governing their practice.44,53
Some UK clinicians had waited to become non-medical prescribers
until national prescribing restrictions had been removed, as prior
to this their practice would have been too limited to be
worthwhile.54 Conversely, one study31 acknowledged that a
‘limited formulary’ might facilitate NMP, as deﬁned limits of
practice enable new prescribers to resist pressure from patients,
managers and clinical colleagues to prescribe outside scope.31
Open formularies were reported to actively facilitate successful
NMP implementation, allowing competent clinicians to prescribe
within their professional code of conduct; reducing patient waiting
times and further easing the workloads of medical prescribers,
who would previously have had to prescribe if the required drug
was absent from the NMP restricted formulary.
Education and support factors
Participants in 27 (63%) of the included studies reported that
the educational processes related to the application of NMP, and
the level and type of support offered to non-medical prescribers by
stakeholders can act as either barriers to or facilitators of
successful implementation of iNMP.
Education: Participants reported that NMP course attendance
was often inﬂuenced by their employers’ willingness to provide
ﬁnancial support for tuition and relief from duties.54 Many
clinicians were unwilling to undertake NMP courses because of
limited incentives, with no ﬁnancial gain following qualiﬁcation,
and pre-existing busy clinical caseloads.54 The cost and time
related to completing course prerequisites such as numeracy,
pharmacology and assessment/diagnostic training were also
barriers.33 Nevertheless, other participants recognised the pre-
requisites as imperative to maintaining quality standards and
ensuring academic ability.33 Many participants felt that the
generic, interdisciplinary nature of NMP courses did not adequate-
ly prepare them to prescribe, with pharmacology content
frequently described as lacking.34,35,44,55 Despite this, courses
were perceived to facilitate NMP by providing access to all
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Table 5
Themes and sub-themes from the included studies, with illustrative quotations from the studies’ participants or authors.
Theme
Sub-theme
Example quotations from included studies n (%) Key elements Studies
Systems Factors 32 (74)
Government and
political factors
4 (9)
The introduction of this initiativewas accompanied by a lot of pressure from the Department of Health on the trusts to push through as many nurses
as quickly as possible.32 p3
1 (2) Drivers 32
The Government had given these free places for training and there was this sort of scrabble for all of us to be put into doing it whether or not we
needed it.35 p2046
1 (2) Funding sources 35
. . . a lack of leadership at both a national and strategic health authority level.33 p8 1 (2) Cohesive thinking and
strategy
33
Participants believed that patient beneﬁt rather than doctor shortage should be the motivation behind nurses prescribing.35 p2049 2 (5) Motives 34,35
Organisational
factors
. . . an institutional strategy is required if non-medical prescribing is to be successful in these settings.32 p3 31 (72)
Ensuring that clinical governance systems were in place and up-to-date was felt to be a critical part . . . 33 p5
It is particularly important that pharmacists develop a culture of safety, do not prescribe outside their areas of competency and are supported in their
prescribing role. Rigorous and robust governance procedures should be in place where pharmacist prescribers operate . . . 42 p830
15 (35) Clinical governance policy
and audit
28,31–35,37–44,51
Logistical barriers to implementation identiﬁed such as information technology issues (lack of access to patient notes in primary care).42 p830 16 (37) Practicalities and logistics 28–30,33–35,40–43,
45,46,48,49,52,74
A colleague completed a course 12months ago and still no policy is in place to enable her to prescribe. This discourages others frommaking the effort
and attending the course.29 p175
26 (60) Policy development and
implementation
28,29,31–45,49–51,
53,54,56,59,61
Formulary I wanted to do the nurse prescribing course for 2 years – until the BNF was opened fully, it was not worth my while.54 p23
Local formulary restrictions and formal agreements (such as an ‘intent to prescribe’) were helpful in deﬁning the limits of practice and assisting
nurses to resist pressure from patients or professionals to prescribe outside of their area of competence . . . 31 p28
The participants were very positive about prescribing and the improvements it had brought to their roles in providing holistic care. However, they all
stated that the limitations of the formulary severely restricted its usefulness.44 p165
It really does frustrateme, especiallywhen I knowexactlywhat I'm looking at and I knowexactlywhat I need to prescribe, but I have to ask the patient
to come back later because I can't prescribe off the [formulary] . . . 44 p165
10 (23) 31–33,35,44,45,52–54,58
Education and
support factors
27 (63)
Education . . . created a feeling of dissatisfaction with my work, as I feel underpaid for the responsibility I have now undertaken in practice. This does not
encourage me to undertake an onerous course for little ﬁnancial recompense.54 p2
18 (42)
. . . access to CPD and formal feedback are areas that need to be developed by education providers andmore formally embraced bymanagers within
each organisation.38 p505
. . . haphazard approach and lack of a formal national infrastructure to guide CPD activity was viewed negatively and appeared to be the cause of
some frustration.35 p2047
11 (26) Continuous professional
development
31,33–35,38,44,54–58
Undertaking any course can be stressful and can generate anxiety. There is anecdotal evidence that the prescribing course, including a mathematics
test that requires a 100% mark to pass, has generated a lot of anxiety among participants.54 p23
GP employers are often unwilling to support courses when they are expected to absorb the cost of locum practice nurse cover.54 p23
As nurses are unable to undertake the prescribing course without the support of a medical supervisor, they are dependent on a doctor agreeing to
supervise.34 p930
. . . the majority of prescribers . . . thought that the prescribing course did not adequately prepare them to prescribe.34 p927
11 (26) NMP course 28,30,34,35,37,44,
52–55,65
Support Participants accessed support from clinicians and peers, non-medical prescribing groups, specialist networks . . . 38 p504
Team processes and communication between the different disciplines within the team impacted on the success of a pharmacist prescriber.43 p130
A number of respondents perceived a lack of medical support as their main reason for not wishing to undertake nurse prescribing training.29 p175
There is a lack of understanding bymedical staff. I know nurses who have undertaken the course and are unable to use their skills. It seems pointless
to do nurse prescribing training unless it can be used effectively.29 p175
Lack of support included lack of supervision, lack of support in the prescribing role, and lack of support from all professionals involved. The lack of
support from management in permitting the implementation of nurse prescribing when the prescriber has qualiﬁed.34 p927
The signiﬁcant contribution that NMP leads play in embedding NMP within organisations should be acknowledged by clearer national guidance for
the role, its responsibilities and workload.33 p9
23 (53) 28–35,37–41,43,49,
54–59,65,81
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Table 5 (Continued )
Theme
Sub-theme
Example quotations from included studies n (%) Key elements Studies
Personal and
professional factorsa
34 (79)
Medical profession I think it’s useful because a lot of the junior doctors obviously rotate through every 3 to 6months and actually if anything someonewho’s a permanent
team member is probably more familiar with the drugs and protocols and the dose ranges.39 p2672
When I have a patient that I know can be followed up by a nurse practitioner I am thrilled because I have got no room in my follow-up clinics . . .
What I have actually done is become dependent. I mean if the nurse practitioner in this department was withdrawn I would not be able to look after
the patients under my care.38 p502
Junior doctors . . . they said that I was taking over their role . . . they were saying, ‘Oh yeah and you’re taking over our role and they won’t need
us.’51p125
I am the doctor; I am supposed to be in charge.39 p2673
Nurses described a lack of support fromGP colleagues and in some cases this extended to GPs speciﬁcally instructing nurses not to prescribe for their
patients.40 p407
26 (60) 29,32,34–40,44,48,
50–56,59,61,76–80
NMP professions I get more job satisfaction now because I can instigate treatment or ﬁrst pills. If the patient is coming for the pill, I can prescribe it and see them again.
It has given me more autonomy.62 p225
I’m not sure that the qualiﬁcation would improve my level of patient care. [Doctors] sign scripts as required.54 p83
There is absolutely no ﬁnancial incentive for taking on the huge responsibility of prescribing . . . 34 p927
In the area that I work I have pockets of deprivation. I know if I am going into those areas I tend not to take my prescription pad with me. I keep it
locked up in the ofﬁce and if they need prescriptions I either ask somebody to come to clinic to collect it or I ask them to get it from the GP just because
I’d feel vulnerable carrying a pad about with me at that time.40 p407
15 (35) 29,34,40,42,53–59,
62,74,76
Service users I would be very happy for pharmacist to prescribemedicines which I take on a regular basis, for example, my inhalers or tablets for reﬂux . . . 41p706
Service users felt that the nurse prescriber knew what she was talking about and had a good understanding of their circumstances and their illness
. . . 64 p146
As far as I’m concerned, I am extremely worried about anyone other than a doctor prescribing any medicines . . . 41 p705
. . . also I think there is no privacy in a pharmacy is there? I don’t think there is anyway . . . You kind of chat over the counter for all and sundry to
hear.49 p116
4 (9) 41,49,60,64
Financial factors 11 (26)
Education and
support
Nurse prescribing education was offered by line managers to the nurses . . . The reason behind this, some suggested, was that there was no direct
cost incurred by the employer at that time. The availability of centrally funded prescribing education therefore appears to have been a signiﬁcant
factor in the uptake of training.35 p2046
The Trust will not allow me to undertake nurse prescribing training. There is no management support  no time or funding29 p174
4 (9) 29,35,42,65
Infrastructure,
practicalities
and logistics
. . . barriers such as cost and access to patient records are preventing beneﬁts from occurring for outpatients in chronic pain30 p33
. . . ﬁnancial pressures, both organisational and personal (eg, cost of indemnity insurance) as barriers to expanding the services offered by
prescribing pharmacists.42 p830
3 (7) 29,30,42
Remuneration Recognition in terms of status and pay for the increased responsibility of prescribing aroused the most emotion and sense of unfairness, and was
found to be a major barrier in the study. Many believed the prescribing role would not be taken seriously until it was remunerated.34 p930
3 (7) 34,56,62
Time and backﬁll I believe it is impossible to carry a large caseload with no one covering it to go on this course (nurse prescribing training) . . . 29 p174 3 (7) 29,40,42
Drugs Reducing prescribing costs in secondary caremeant that only onsite treatment and emergencymedication are ﬁnanced, and all other prescribing has
to go through primary care via the General Practitioner.35 p2048
Another frustration was their inability to prescribe for patients attending their clinic if the patient’s GP was located in another Trust.40 p407
4 (9) 32,35,40,75
CPD= continuing professional development, GP=general practitioner, NMP=non-medical prescribing.
a Includes thoughts and perceptions regarding the acceptability and value of NMP.
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associated professions, whereas small uni-professional cohorts
would limit a university’s capacity to offer and deliver.34,35
Accessing a medical mentor to complete the course was perceived
as a barrier, with variability of medical professionals’ willingness to
undertake this role, and a perception that medical mentorship was
frequently inadequate.28,34,53
Participants reported that a formal national infrastructure to
guide CPD would be beneﬁcial, as support from managers,
availability of specialty courses, funding and time were highlighted
as barriers to appropriate CPD activities and courses.33,35,38,54 This
in turn limited a prescriber’s ability to maintain awareness of the
current evidence base, directly inﬂuencing NMP utilisation in
practice.33,35,38,56 The introduction of ‘buddy systems’ alongside
regular in-house multidisciplinary CPD were positive and eco-
nomical in maintaining evidence-based medicines use.44,57
Support: Type and level of support to implement, maintain and
develop NMP were reported to depend on the participant’s reasons
for commencing NMP and their role within the health ser-
vice.29,33,34,58 Engagement and support from all parties, especially
medical staff and health managers, were essential for planning and
successful implementation.34,55,59 Support from medical profes-
sionals as mentors during training and post-qualiﬁcation was
strongly emphasised as important, and an NMP facilitator.
However, time to undertake mentored activities was recognised
as a potential barrier.34,37 Support from healthcare managers and
government were reported as key to ensuring provision of policy
and funding, overcoming barriers presented by other groups, and
facilitating organisational pressure to enable implementation of
NMP.29,32,35,55,59 Support from within the NMP professions was
reported as fundamental to: advocate for colleagues to be trained
to prescribe; act as buddies to reduce feelings of isolation; and
develop services.34,37,56,57 The adoption of NMP lead roles was
reported as crucial for coordination and promoting the beneﬁts of
NMP, ensuring that organisations provide safe practice environ-
ments and liaison with higher education providers.33,39 Service
users’ poor knowledge and understanding of the level of education
and experience required by non-medical prescribers were
acknowledged as potential barriers.49,60 Participants accepted that
support from service users was vital,49,60 with service user
consultation recognised as fundamental when contemplating
health service redesign.41,49,60
Personal and professional factors
Participants in 34 (79%) studies reported that the thoughts and
perceptions relating to acceptability and value of NMP had
signiﬁcant impact on its implementation and utilisation.
Medical profession: Negative thoughts and perceptions held by
medical professionals were widely perceived to result from a lack
of understanding of NMP roles and responsibilities, causing fear of
deskilling or loss of power and/or control.29,32,39 Medical practi-
tioners reported confusion about autonomy, responsibility and
insurance, which in turn led to a lack of support for NMP.32
Practitioners working in private practice acknowledged the threat
of NMP competing for business with medical colleagues,56 and
junior doctors felt that NMP threatened their roles.51 Some general
practitioners wanted to maintain ownership of patients in health
systems in which general practices have responsibility for direct
funding of medicines.32,35
Conversely, medical professionals with positive feelings to-
wards NMP acknowledged the beneﬁts to service users, healthcare
staff and the health economy.36,38 They reported enhancement in
service provision, efﬁciency and patient care.38 Doctors acknowl-
edged that non-medical prescribers who had a strong and
established relationship with the medical team had the experience
and knowledge to prescribe successfully.39,44,61 NMP was reported
to be extremely helpful in reducing and avoiding waiting lists,
especially in specialties where long-term drug monitoring is
prevalent.32,36,38 When doctors were unable to see patients in a
timely manner, a non-medical prescribers’ ability to initiate, titrate
and modify treatments had a positive effect on patients’ access to
medicines.32,36–39 It was also highlighted that non-medical
prescribers, unlike junior doctors, are permanent team members,
and therefore become more familiar with drugs, protocols and
dose ranges.39 Recognition of these beneﬁts was reported to drive
medical professionals to advocate for the inclusion of NMP into
local healthcare systems.32,36–39
NMP professions: The main facilitator observed by participants
was job satisfaction.54,55,62 Some participants reported that the
inclusion of NMP into their roles gave them more autonomy,
improving the level of patient care they offered.54,55,62 In contrast,
some participants reported that the risk and responsibilities
associated with NMP increased stress and anxiety, restricting time
spent on traditional areas of practice.29,54 Many participants,
although supportive, recognised that NMP would not enhance
their individual roles within interdisciplinary teams, as medical
prescribers are readily available to prescribe.29,53,54,63
The phase of an individual’s career was perceived to affect the
uptake of NMP into practice. Many clinicians with the high level of
experience required prior to NMP training might prioritise non-
clinical job roles, pursue other areas of study or be nearing
retirement, and not motivated to undertake NMP.54,56 Participants
acknowledged the lack of additional remuneration offered to non-
medical prescribers as a barrier.34,56,62 Speciﬁcally, the enhanced
responsibility and associated safety risks, with no reward (ﬁnancial
or otherwise), was reported to deter many.40,53,54
Service users: Most participants were happy with NMP services,
citing closer relationships with non-medical prescribers than
doctors, due to the time limitations within medical clinics. NMP
services were often more convenient, providing faster access to
required treatment compared to traditional medical care.60,64
Conversely, participants in two studies reported that they felt
prescribing responsibilities belong to medical professionals and
were unsure about the qualiﬁcations possessed by non-medical
prescribers.41,49 A ﬁnal subgroup reported that they were happy for
non-medical prescribers to monitor long-term medication use;
however, assessment of a new medical condition was felt to be the
job of the medical practitioner.41 To avoid poor uptake of NMP
services, participants recommended that service users be con-
sulted at all levels and phases of service planning, with education
of service users essential if these key stakeholders were not to be a
barrier to successful implementation.41,49,60,64
Financial factors
Participants in 11 (26%) studies reported ﬁnancial factors to be
key facilitators or barriers to NMP. Financial factors underpinned
all themes/sub-themes, with inadequate funding creating and
reinforcing signiﬁcant barriers to successful implementa-
tion.32,35,62,65 Funding for time and education should include
ﬁnancial support for both completion of the NMP course and
CPD.29,35,42,65 Further, appropriate ﬁnancial resources were re-
quired to backﬁll roles previously undertaken by non-medical
prescribers whilst training and post implementation of NMP into
their roles.29,35,40,42 Participants advised when planning, imple-
menting and developing any NMP services, organisations must
ensure they have sufﬁcient ﬁnancial resources for the necessary
infrastructure, logistics, remuneration of staff and other practical
implications of NMP such as administrative support and insur-
ance.30,34,42,56 Participants also highlighted the funding of drugs
themselves as a possible barrier. Issues related to equity and
equality of patient care, especially where patient care crosses
borders, organisational boundaries and/or funding pools, were
considered immoral, frustrating, and a barrier to good practice and
successful implementation.32,35,40
Characteristics of quantitative studies
Study characteristics
Seven quantitative studies were included in the systematic
review;63,66–71 their characteristics are summarised in
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Table 6. More detailed characteristics are available in Table 7 (see
eAddenda for Table 7).
Study methods
All seven included studies used survey methodology.63,66–71
Distribution of questionnaires was varied, with four (57%) studies
using postal questionnaires,66,68–70 two (29%) using online
questionnaires,63,71 and one (14%) providing participants with a
choice of both methods.67 The studies were undertaken in three
countries from 2001 to 2011, with ﬁve (71%) in the UK, one (14%) in
Canada and one (14%) in USA.
Participants
A total of 4773 participants were recruited across the seven
studies.63,66–71 The key stakeholders that were recruited were
nurses (87%), pharmacists (8%), health service managers (5%) and
allied health/optometrists (<1%). A small percentage of partici-
pants (<1%) did not disclose their job roles or profession.
Intervention
Most of the included studies investigated nurse iNMP (n = 4,
57%).66–69 Pharmacists were the only other profession individually
investigated (n = 1, 14%).63 One study investigated both nurse and
pharmacist iNMP (14%),70 with one further study investigating
iNMP as a whole, including all potential professionals (14%).71 Six
(86%) studies included participants working across community
and hospital settings,66–70 with one (16%) focusing on hospital
care.63 Five (71%) studies encompassed all healthcare special-
ties;63,66,68,70,71 the remaining studies focused on individual
specialties including oncology (14%) and emergency/urgent care
(14%).67,69
Outcomes
All seven studies contained at least one quantitative survey
question relating to barriers or facilitators of NMP.63,66–71 Data
supported three (75%) of the four themes synthesised from the
qualitative studies. Four (57%) studies contained data relating to
‘systems factors’,66–68,71 ﬁve (71%) studies ‘education and
support’,66,68–71 and ﬁve (71%) studies ‘personal and professional
factors’.63,66–68,70 No studies contained data directly relating to
‘ﬁnancial factors’.
Quality assessment
Quality scores of the quantitative studies are summarised in
Table 6 and ranged from 14 to 22 (mean 18). The individual quality
criteria met by the studies are presented in Table 8 (see eAddenda
for Table 8).
Results and synthesis of quantitative studies
Table 9 summarises the results of individual studies.
Systems factors
Four studies investigated systems factors.66–68,71 Results
highlighted local policy and lack of access to computer-generated
prescriptions as key barriers.66,68 One study67 assessed barriers
due to time, capacity and resources, ﬁnding that whole health
organisations, rather than individual directorates, were responsi-
ble for limiting use of iNMP due to these factors.67 One study71
reported that 86% of employers had up-to-date policies in place,
facilitating quality and safe use of NMP. Key elements of these
policies were: agreed and documented scope of practice; regular
clinical services audit; and standardised procedures for communi-
cating updates regarding safety warning and drug alerts.66
Education and support factors
Two studies investigated education and support factors.68,71
Results revealed that NMP course content, support following
qualiﬁcation, and adequate access to CPD were key factors.71
Barriers were examined across three studies.66,68,70 Results
identiﬁed a lack of support from medical professionals and peers,
and deﬁciency of adequate supervision when training to pre-
scribe.66,68,70One study investigated factors inﬂuencing healthcare
managers’ decisions to send clinicians on the NMP course.69
Facilitating factors that were identiﬁed were: increasing autono-
my; improvements in patient care; improvements in clinicians’
pharmacology knowledge; and improved accountability. Barriers
were: time; factors related to the backﬁll of course candidates;
medical supervisor requirements; and a limited formulary being
too restrictive to be beneﬁcial.69
Personal and professional factors
Three studies66,68,70 investigated personal and professional
factors. Objections and concerns by medical professionals and
pharmacists regarding competency, liability and competition were
found to be important external factors.68 Internal factors such as a
professional’s caseload and fear of litigation were also demon-
strated.70One study67 found that time, capacity and resources were
barriers, which were reported in some cases as being induced by
nursing and medical directorates, with further reasoning not
reported. One study63 investigated the level of inﬂuence of factors
affecting an individual’s decision to seek or not seek NMP
authorisation. Those that had chosen to seek authorisation
reported a high relevance to practice and increased efﬁciency/
job satisfaction as key motivators. Clinicians who decided not to
seek authorisation reported concerns regarding increased liability
and poor relevance to their practice as key factors not to
prescribe.63
Integration of qualitative and quantitative data
Data from 12 117 participants (combined from the qualitative
and quantitative studies) were integrated. Table 10 shows the total
number of participants from each stakeholder group involved in
iNMP included in the integration.
Data from the qualitative and quantitative components of the
systematic review were brought together in the integration matrix
(Table 11) and used to construct the resultant ‘NMP Implementa-
tion Framework’ (Figure 2). Data extracted from the quantitative
studies corroborated the existence and importance of the
subthemes identiﬁed in three themes developed from the
qualitative studies. Integration was undertaken for six (75%)
Table 6
Characteristics and quality of the included qualitative studies (n = 7).
Study Survey method Year of data collection Specialty Total
(n)
Number of participants from each profession Qualitya
(0 to 48)
Courtenay66 Postal questionnaire 2006 Various 1992 1992 nurses 21
Courtenay71 Online questionnaire 2010 to 2011 Various 883 793 nurses, 33 managers, 36 pharmacist, 9 allied
health and optometrists, 12 n/s
22
Farrell67 Online or postal questionnaire n/s Oncology 103 103 nurses 17
Gumber70 Postal questionnaire 2010 Various 20 18 nurses, 2 pharmacists 14
Hutchison63 Online questionnaire 2010 Various 342 342 pharmacists 19
Kaplan68 Postal questionnaire 2001 Various 1241 1241 nurses 20
Larsen69 Postal questionnaire 2003 Emergency/urgent care 192 192 managers 14
n/s = not stated.
a Quality Assessment Tool for Studies with Diverse Designs.23
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Table 9
Findings from quantitative studies categorised under the themes generated by the analysis of the qualitative studies.
Theme
Study
General focus of the study Speciﬁc ﬁndings of the study, reported by n (%) participants Qualitya
(0 to 48)
Systems Factors Mean 20
Courtenay66 Barriers to iNMP: local policy, 619 (66%) 21
national policy, 87 (9%)
unable to use computer-generated prescriptions, 575 (61%)
access to medical records, 26 (3%)
Kaplan68 Barriers to iNMP: restricted formularies, 183 (24%) 20
Farrell67 Time, capacity and resources
were reported to be barriers
induced by:
the health organisation, 41 (41%) 17
nursing directorate, 14 (14%)
medical directorate, 22 (22%)
Courtenay71 89% of employers had up-to-date
NMP policies in place. Policies
dictated:
regular audit and review of clinical services, 561 (74%) 22
regular feedback data re prescribing practice, 328 (44%)
access own prescribing practice data, 281 (37%)
agreed scope of practice with employers, 642 (85%)
supplied with safety warnings, drug alerts, etc, 678 (90%)
NMPs involved in the development of local formularies/guidelines, 357 (48%)
Education and support factors Mean 18
Courtenay71 Facilitators of iNMP: adequate support following qualiﬁcation to undertake iNMP, 304 (47%) 22
adequate access to support prescribing role, 561 (74%)
Courtenay66 Barriers to iNMP: lack of peer support, 126 (13%) 21
Kaplan68 Barriers to iNMP: medical professional availability to support, 33 (4%) 20
Gumber70 Barriers to iNMP: adequate supervision: strongly agree, 4 (20%); agree, 10 (50%); undecided, 4 (20%); disagree 2 (10%) 14
Facilitators of iNMP: prescribing course content: strongly agree, 4 (20%); agree, 12 (60%); undecided, 2 (10%); disagree 2 (10%)
support and guidance from medical professional: strongly agree, 11 (55%); agree, 9 (45%)
Larsen69 Facilitators of manager’s decision
to send clinicians
to a NMP course:
autonomy, (44%); patient care, (37%); improve clinicians’ pharmacology, (38%); improve knowledge of
accountability, (34%); requested by staff, (18%); recruitment/retention, (11%); organisational drivers, (14%)
14
Barriers to manager’s decision to
send clinicians to a NMP course:
time, (11%); backﬁll, (17%); formulary too limited to be beneﬁcial, (29%); ﬁnding medical supervisor, (11%);
poor medical support, (2%); funding of drugs, (<1%); poor intra-professional support, (2%)
Personal and professional factors Mean 18
Courtenay66 Barriers to iNMP: objections by medical professionals/pharmacists, 153 (16%) 21
Kaplan68 Barriers to iNMP: medical professionals’ concerns regarding liability, 183 (24%) 20
competition between medical and non-medical prescribers, 33 (4%)
Gumber70 Barriers to iNMP: conﬂicts with medical staff: agree, 9 (45%); undecided, n (5%); disagree, 4 (20%); strongly disagree, 6 (30%) 14
signiﬁcant increases in caseload: strongly agree, 2 (10%); agree, 11 (55%); undecided, 5 (25%); disagree, 1 (5%);
strongly disagree, 1 (5%)
fear of litigation; agree, 7 (35%); undecided, 7 (35%); disagree, 5 (25%); strongly disagree, 1 (5%)
Farrell67 Time, capacity and resources
were reported to be barriers
induced by:
nursing directorate, 14 (14%) 17
medical directorate, 22 (22%)
Hutchison63 Level of inﬂuence on
individual’s decision to seek
NMP authorisation, as rated by
clinicians who had applied for
authorisation to prescribe:b
relevance to practice: strongly (70%); moderately (22%); somewhat (5%); slightly (3%); not at all (0%) 19
increased efﬁciency: strongly (62%); moderately (22%); somewhat (3%); slightly (11%); not at all (3%)
importance to the profession: strongly (56%); moderately (22%); somewhat (11%); slightly (3%); not at all (8%)
time: strongly (8%); moderately (19%); somewhat (6%); slightly (11%); not at all (56%)
job satisfaction: strongly (37%); moderately (29%); somewhat (11%); slightly (9%); not at all (14%)
concerns, increased liability: strongly (17%); moderately (17%); somewhat (17%); slightly (34%); not at all (14%)
Level of inﬂuence on
individual’s decision to seek
NMP authorisation, as rated by
clinicians who decided not to
apply for authorisation to
prescribe: b
relevance to practice: strongly (37%); moderately (26%); somewhat (17%); slightly (6%); not at all (15%)
increased efﬁciency: strongly (16%); moderately (16%); somewhat (17%); slightly (14%); not at all (36%)
importance to the profession: strongly (14%); moderately (13%); somewhat (21%); slightly (11%); not at all (41%)
time: strongly (18%); moderately (18%); somewhat (17%); slightly (9%); not at all (39%)
job satisfaction: strongly (7%); moderately (15%); somewhat (16%); slightly (18%); not at all (45%)
concerns, increased liability: strongly (23%); moderately (23%); somewhat (23%); slightly (16%); not at all (15%)
CPD = continuing professional development, GP = general practitioner, NMP = non-medical prescribing.
a Includes thoughts and perceptions regarding the acceptability and value of NMP.
b Scale: not at all, slightly, somewhat, moderately, strongly.
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subthemes within these themes. No data from the quantitative
studies disagreed with the thematic synthesis. Integration was not
possible for ﬁnancial factors, government and political factors
and service users sub-themes, as no data relating to these themes/
sub-themes were retrieved from the quantitative studies.
Discussion
The evidence from this systematic review suggests that
successful implementation of iNMP requires a coordinated,
transparent and inclusive approach at all systems levels.32,33,50
From governments to local clinical departments or businesses,
the development of laws, regulations, guidelines, policies and
procedures must be created with consistency, and involve
consultation with all key stakeholders. A strategic, collaborative
and consultative implementation process is fundamental to
manage potential barriers, including personal and professional
self-interest, professional territorialism, fear of change, and poor
quality or unsafe clinical practice.51,56 These ﬁndings conﬁrm
results from a large study evaluating nurse and pharmacist
prescribing in the UK,72 which highlighted that a lack of local
planning and strategic vision had previously been a key barrier to
NMP.72 With economic savings driving implementation, it is
paramount that robust local clinical governance policy exists to
protect both those using NMP services and non-medical pre-
scribers themselves.32,33,66,71 Policy should be locally deﬁned
within a national framework, as different clinical settings will
require unique procedures and safeguards, depending on locality,
availability of immediate clinical support and professional
specialty.34 NMP should be integrated as an additional clinical
skill, complementing traditional expertise and scope of practice, to
enhance patient care.33,34 It is essential to clearly deﬁne scope,
parameters, boundaries, accountability and lines of responsibility,
in order to avoid risks associated with potential confusion and
ambiguity,34 alongside communication and documentation poli-
cies, incident reporting processes, and CPD requirements to embed
a culture of quality and safety.34,35,42,43 Health organisations
should work together to ensure that bureaucracy does not limit
clinicians’ abilities to provide quality patient-centred care by
adopting innovative service designs.33,36,40 To ensure the longevity
and future expansion of NMP, health organisations should aim to
Table 10
Total number of participants included in the systematic review.
Stakeholder group Total
n (%)
Nurses 8466 (70)
Service users 2527 (21)
Pharmacists 625 (5)
Managers 242 (2)
Medical doctors 114 (<1)
NMP leads 72 (<1)
Others 42 (<1)
Administrative staff 20 (<1)
Allied health professionals 9 (<1)
Total 12117 (100)
NMP = non-medical prescribing.
Table 11
Integration matrix. The rows of the matrix represent the subthemes developed from synthesis of the qualitative studies, and the columns contain citations of the quantitative
studies.
Theme Quantitative studies (n = 7)
Sub-theme Courtenay66 Courtenay71 Farrell67 Gumber70 Hutchison63 Kaplan68 Larsen69
Systems factors
Government and political factors N N N N N N N
Organisational factors Y Y Y N N N N
Restricted formulary N N N N N Y N
Education and support
Education N Y N Y N N Y
Support Y Y N Y N Y Y
Personal and professional factors
Members of the medical profession Y N Y Y N Y N
Members of the NMP professions Y N Y Y Y N N
Service users N N N N N N N
Financial factorsa – – – – – – –
N = not identiﬁed as a relevant factor in the quantitative studies, Y = identiﬁed as a relevant factor in the quantitative studies.
NMP = non-medical prescribing.
a Financial factors were not assessed in any of the quantitative studies.
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Figure 2. NMP Implementation Framework. Factors to consider when implementing independent NMP.
CPD = continual professional development
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future-proof services through workforce and succession planning,
alongside clinical outcome and cost-effectiveness audits to ensure
ongoing quality, effectiveness and funding.
Owing to innovations in medical science, clinicians, health
organisations and authorities have recognised that legally
restricted formularies may quickly become outdated.31,44,52,53
Restrictions within scope of practice are thought to deter potential
non-medical prescribers from training, and lead to professional
frustration and low levels of engagement for those who are
qualiﬁed.54 Risk may be managed via local formulary deﬁned in
organisational policy. This method has the beneﬁt of ﬂexibility
without restrictions in law, whilst protecting the local prescribers
and service users.32,54 Selection criteria alongside academic and
professional prerequisites are currently utilised by health organi-
sations and higher education institutions to ensure academic
ability, safeguard quality and select suitable NMP training course
candidates.33 Although courses fulﬁl nationally agreed standards,
the evidence suggests that a lack of profession-speciﬁc content
may lead to candidates feeling underprepared.34,35,55 Further, lack
of access to a medical mentor may impede qualiﬁcation, with
inconsistencies in mentorship quality affecting a clinician’s
conﬁdence to prescribe.28,34,68 It has been suggested that national
frameworks be developed that govern CPD activity and facilitate
access time and funding.33,35,38,54 These factors therefore require
further investigation to ensure high-quality education and
resource optimisation.
The positive or negative thoughts and perceptions of both
individual stakeholders and their wider professions appear
intimately related to the level of support offered to non-medical
prescribers, their educational activities and NMP services. Im-
proved job satisfaction due to increased autonomy and the ability
to provide improved patient care are key drivers for clinicians
undertaking NMP roles.54,55,62 Conversely, increased job stress and
anxiety, associated safety risks and restricted time to complete
traditional roles, with no increase in remuneration for the
increased responsibility, are key barriers.29,54 The engagement of
medical professionals in consultative, planning and governance
roles, and as clinical mentors34,55,59,68 may minimise barriers
associated with the medical profession, due to fears of: deskilling,
loss of power and job roles, competition to earnings and confusion
regarding autonomy, responsibility, liability and insurance.29,32,39
Consistent with the ﬁndings of previous research,73 this review
emphasises the beneﬁts of adopting NMP lead roles within health
organisations to aid in overcoming systems, personal and
professional barriers,33,39 and reducing feelings of professional
isolation, where the number of prescribers are limited.
To promote NMP implementation and practice, health organi-
sations should undertake a thorough economic evaluation as part
of planning and development, securing the appropriate ﬁnances
required for success.30,34,42 To ensure no detrimental effects to
patient care or clinician job satisfaction it is recommended that
complexities related to funding streams crossing organisational
boundaries or fragmented health systems should be resolved prior
to offering NMP services.32,35,40 Whilst the potential economic
savings act to engage many individuals or professions with the
beneﬁts of utilising NMP, some ﬁnancial factors act to resist NMP
through difﬁculties in modernising funding streams and increased
clinical responsibility with potentially no increase in remunera-
tion. If NMP is to further grow and develop, these barriers must be
acknowledged, planned for and resolved across all aspects of the
health economy.
This review used rigorous systematic methods with a synthesis
strengthened by the engagement of a multidisciplinary research
team, including both registered non-medical prescribers and non-
prescribers. This combination ensured specialist knowledge of
iNMP alongside speciﬁc disciplinary perspectives, facilitating a
rigorous analytical process. Most included studies were limited to
nursing and a small range of Western countries, potentially
limiting transferability of the results across all clinical and
professional specialties internationally. No temporal or spatial
analysis was undertaken within the review; therefore, caution is
recommended when interpreting the contemporary nature of the
barriers or facilitators into individualised contexts.
This is the ﬁrst mixed-methods systematic review to investigate
the barriers to and facilitators of iNMP. Integration of the
quantitative and qualitative data demonstrates, with strong
agreement, multifactorial and context-speciﬁc variables existing
within four explicit themes. The evidence supports that when
factors are acknowledged and accommodated, they become
facilitators, but may become barriers when they are not. Clinical
physiotherapists and other clinicians should consider whether
these factors have been adequately addressed before training to
become non-medical prescribers. Politicians, policy and healthcare
managers and clinicians should use the resulting NMP implemen-
tation framework to ensure the safe and successful adoption,
implementation and utilisation of physiotherapist prescribing.
Where physiotherapist prescribing is currently outside the legal
scope of practice, the resulting NMP Implementation Framework,
and this review’s evidence, should be core to the implementation
strategy of physiotherapy professional bodies wishing to adopt
NMP practice. There is a clear need for future research to evaluate
the personal and professional motivations for physiotherapy
prescribing internationally, implementation strategies, and the
efﬁcacy in terms of clinical and cost-effectiveness of services
employing iNMP. To fully understand the long-term uses of NMP it
is paramount that variables such as profession, specialty,
geographic location, clinical indications and funding models are
assessed alongside the needs of service users, communities and the
impact on all stakeholders.
What is already known on this topic: Non-medical pre-
scribing is undertaken by various professions internationally.
Non-medical prescribing may be supplementary (ie, via a
clinical management plan in partnership with a medical prac-
titioner) or independent (ie, the non-medical professional
prescribes autonomously).
What this study adds: Qualitative studies have identified
barriers and facilitators to non-medical prescribing in: political/
organisational factors; whether a formulary is used; education
and support; personal and professional factors among the
medical profession, other professions, and service users;
and financial factors. Quantitative studies confirm these fac-
tors. Based on this evidence, an implementation framework is
proposed to assist professional bodies, politicians, policy-
makers, healthcare managers and clinicians to ensure that a
non-medical prescribing system would be introduced safely
and successfully.
Footnotes: a NVivo 11, QSR International, Melbourne, Australia.
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